Cambridge startup Qureight has raised $20m in Series B funding led by Molten Ventures to build a 'foundation model' for the chest that can speed drug trials by generating disease-specific AI imaging m…
Bristol Myers Squibb will become the first life sciences company to purchase Nvidia's latest DGX SuperPOD, powered by the newly unveiled Vera Rubin architecture, marking a significant escalation in AI…
Bristol Myers Squibb is expanding its partnership with Nvidia to boost AI computing power for drug discovery, building on its AI Center of Excellence using Nvidia's DGX SuperPOD infrastructure that ha…
Bristol Myers Squibb (BMS) announced it is deploying its second NVIDIA DGX SuperPOD, built on eight DGX Vera Rubin NVL72 systems, to create what it calls the most powerful and energy-efficient AI clus…
Roche's divarasib beat Amgen's Lumakras and Bristol Myers Squibb's Krazati in a head-to-head Phase 3 trial for KRAS G12C non-small cell lung cancer, showing statistically significant improvements in p…
Anthropic CEO Dario Amodei tempered expectations for AI-driven scientific breakthroughs at the company's 'The Briefing: AI for Science' event, suggesting the 'compressed 21st century' he predicted mig…
Immunai announced a discovery collaboration with Boehringer Ingelheim valued at up to $15 million through 2027. The partnership will apply Immunai's single-cell AI platform to identify T-cell targets …
The US Treasury is assessing whether to expand outbound investment screening to include biotechnology deals with Chinese firms, following bipartisan pressure from lawmakers. Representatives John Moole…